- Home
- APM vs PPBT Comparison
APM vs PPBT Comparison
Compare APM & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- PPBT
- Stock Information
- Founded
- APM 2010
- PPBT 2010
- Country
- APM United Kingdom
- PPBT Israel
- Employees
- APM N/A
- PPBT N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- PPBT Health Care
- Exchange
- APM Nasdaq
- PPBT Nasdaq
- Market Cap
- APM 6.9M
- PPBT 6.2M
- IPO Year
- APM 2018
- PPBT N/A
- Fundamental
- Price
- APM $1.42
- PPBT $2.23
- Analyst Decision
- APM
- PPBT Strong Buy
- Analyst Count
- APM 0
- PPBT 1
- Target Price
- APM N/A
- PPBT $33.00
- AVG Volume (30 Days)
- APM 461.1K
- PPBT 268.4K
- Earning Date
- APM 08-19-2025
- PPBT 08-06-2025
- Dividend Yield
- APM N/A
- PPBT N/A
- EPS Growth
- APM N/A
- PPBT N/A
- EPS
- APM N/A
- PPBT N/A
- Revenue
- APM N/A
- PPBT N/A
- Revenue This Year
- APM N/A
- PPBT N/A
- Revenue Next Year
- APM N/A
- PPBT N/A
- P/E Ratio
- APM N/A
- PPBT N/A
- Revenue Growth
- APM N/A
- PPBT N/A
- 52 Week Low
- APM $0.46
- PPBT $2.00
- 52 Week High
- APM $7.49
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- APM 51.44
- PPBT 39.30
- Support Level
- APM $1.21
- PPBT $2.09
- Resistance Level
- APM $1.44
- PPBT $2.31
- Average True Range (ATR)
- APM 0.13
- PPBT 0.15
- MACD
- APM -0.04
- PPBT -0.01
- Stochastic Oscillator
- APM 34.37
- PPBT 8.85
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.